Navigation Links
Japanese Researchers Develop New Smallpox Vaccine
Date:3/10/2009

No serious side effects are found in latest test, study reports,,

TUESDAY, March 10 (HealthDay News) -- A third-generation tissue-cultured smallpox vaccine shows promise, Japanese researchers report.

"The threat of smallpox bioterrorism has prompted reconsideration of the need for smallpox vaccination," the researchers noted. "Serious events associated with first-generation vaccines #133; have raised obstacles to vaccination campaigns in the United States."

Second-generation vaccines also cause a high rate of serious side effects, they said.

"Developing a vaccine that is safer than first-generation vaccines yet highly immunogenic [producing immunity or an immune response] is crucial to constructing a prevention plan in the event of bioterrorist attack," they added.

The researchers studied the clinical and immunological responses to the LC16m8 vaccine in 1,692 adults who had previously been vaccinated against smallpox and 1,529 adults who had not been vaccinated. LC16m8 is a live, attenuated (reduced in strength) vaccine.

Participants were examined 10 to 14 days after being vaccinated. The researchers found that antibodies developed in about 90 percent of those who had not been previously vaccinated, and an effective booster response occurred in 60 percent of those who had previously been vaccinated. None of the participants suffered serious side effects.

The study "offers supported evidence for the safety of LC16m8 vaccine in adults," wrote Dr. Tomoya Saito, of Keio University in Tokyo, and his colleagues."LC16m8 vaccine appears to be a viable alternative to first-, second- and other third-generation vaccines in a smallpox [bioterrorism] preparedness program."

The study appears in the March 11 issue of the Journal of the American Medical Association.

More information

The U.S. Centers for Disease Control and Prevention has more about smallpox.



-- Robert Preidt



SOURCE: Journal of the American Medical Association, news release, March 10, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
2. STAAR Surgical to Purchase Canons Interest in Japanese Joint Venture
3. Chemo Drug Improves Stomach Cancer Survival for Japanese Patients
4. SNM/Nihon Medi-Physics sponsor new fellowship program for Japanese physicians
5. STAAR Surgical Completes $5M Debt Financing for Purchase of Japanese Joint Venture
6. Nihon LocalSoft Designs New Japanese Software for IRadimed Corporations Award-Winning MRidium MRI Infusion System
7. Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market
8. Health and Beauty Come Full Circle: Chado-En Brings Full Benefit of Japanese Green Tea to Spas
9. Japanese encephalitis virus causes double trouble to brain
10. Fondness for Fish Keeps Japanese Hearts Healthy
11. First Implant of DuraHeart(TM) Left Ventricular Assist System (LVAS) in Japanese Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Japanese Researchers Develop New Smallpox Vaccine
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
Breaking Medicine Technology: